[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Aristotle University Of Thessaloniki\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":743},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,32,0,25,[9,53,87,123,155,187,215,247,271,292,330,357,389,419,442,476,505,525,549,574,596,627,656,692,715],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100465768","high-frequency-rf-current-effects-on-muscle-pain-and-function-100465768",false,"NCT05345015","High Frequency RF Current Effects on Muscle Pain and Function","Acute and Chronic Effects of High Frequency RF Electrical Current on Pain and Muscle Function in Individuals With Musculoskeletal Pain","Individuals with Muscle Injury\n\nInclusion Criteria:\n\n* Age over 18 years.\n* Athletes: amateur soccer players or sprinters with regular, systematic training.\n* Suspected Grade I or II hamstring strain.\n* Cessation of training due to injury.\n* No surgical intervention in the previous year (for initial assessment as potential participants).\n\nExclusion Criteria:\n\n* History of injury to the same muscle (ipsilateral side) within the last 6 months.\n* Other injury to the posterior aspect of the thigh.\n* Other injuries or chronic pain in the trunk or lower limbs.\n* Use of non-steroidal anti-inflammatory drugs (NSAIDs) in the 3 months prior to the injury.\n\nIndividuals with Acute Low Back Pain\n\nInclusion Criteria:\n\n* Age over 18 years.\n* Pain located between the lower ribs and the gluteal folds (top of the buttocks).\n* Pain occurred on fewer than half of the days over the preceding six months.\n* Pain intensity $\\\\ge$ 6\u002F10 on the Visual Analogue Scale (VAS).\n* Pain related to one or more of the following:\n\n  * Lumbar facet joints\n  * Sacroiliac joints\n  * Lumbar intervertebral discs\n  * Muscles, tendons, or ligaments of the lumbar and sacral region\n  * Other bony structures of the lumbar spine\n* Discontinuation of non-steroidal anti-inflammatory drugs (NSAIDs) or analgesics:\n\n  * 1 day prior to measurement\n  * 48 hours after measurement\n\nExclusion Criteria:\n\n* Radiographic evidence of inflammatory disease affecting the spine.\n* Spinal fracture.\n* Significant genetic structural abnormality of the spine.\n* Pregnancy.\n* Psychiatric disorders.\n* Receipt of systemic medication or treatment in the last 3 months.\n* Presence of neurological deficits (sensory, motor, or reflexes).\n* Receipt of TENS or TECAR therapy within the last year.\n\nIndividuals with Chronic Low Back Pain\n\nInclusion Criteria:\n\n* Episodes of low back pain (between the lower rib margin and the gluteal fold) for at least half of the days during the last 6 months.\n* Pain intensity $\\\\ge$ 20% on the Visual Analogue Scale (VAS).\n\nExclusion Criteria:\n\n* Spinal stenosis.\n* Radiographic evidence of inflammatory disease affecting the spine.\n* Vertebral fracture.\n* Presence of spondylolisthesis or spondylolytic lesion (spondylolysis).\n* Significant genetic structural abnormality of the spine.\n* Daily, severe low back pain.\n* Pregnancy.\n* Use of medications that might influence heart rate or blood pressure.\n* Psychiatric disorders.","ALL","18 Years","65 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this study is to examine the acute and chronic effects of high frequency electrical current transfer (frequently called \"TECAR\") on pain and functional movement in individuals with a musculoskeletal injury or pain. The participants will be assigned into an experimental or a control group and outcome measures will be measured prior to, after, 24 and 48 hours following a single intervention session (Acute effects) as well as 3 and 6 months after the intervention (chronic effects).",[28,29,30,31,32,33,34],"Transcutaneous Electric Nerve Stimulation","Chronic Low-back Pain","Hamstring Injury","Muscle; Injury, Quadriceps (Thigh)","Physical Therapy","Calf Muscle Pulled","Acute Low Back Pain",[36,37,38,39],"Sport injuries","TECAR therapy","Low back pain","Muscle injury","RECRUITING","2026-06-23",{"date":43,"type":44},"2026-06-26","ACTUAL",{"date":46,"type":44},"2022-09-01",{"date":48,"type":22},"2029-12-31",{"name":50,"class":51},"Aristotle University Of Thessaloniki","OTHER",2,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":17,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},"100641602","phase-4-enteral-lipid-supplementation-and-bronchoplumonary-dysplasia-of-premature-infants-100641602","NCT07652684","Enteral Lipid Supplementation and Bronchoplumonary Dysplasia of Premature Infants","Enteral Lipid Supplementation and Bronchoplumonary Dysplasia of Premature Infants: A Randomized Controlled Trial (The PRELUDE Trial)","PRELUDE","Inclusion Criteria:\n\nInfants born at Papageorgiou Hospital in Neonatology Department and NICU of Aristotle University of Thessaloniki with GA equal to or less than 29 weeks are eligible to participate in the study.\n\nExclusion Criteria:\n\nCongenital malformations, chromosomal abnormalities or critical illness with short life expectancy.\n\nStudy participation requires written informed parental consent within 48h after birth.","24 Weeks","29 Weeks",{"count":64,"type":22},74,[66],"PHASE4","The Impact of Omega-3 (DHA - Docosahexaenoic Acid) and Omega-6 (ARA - Arachidonic Acid) Supplementation on the Development of Bronchopulmonary Dysplasia in Extremely and Very Preterm Infants (24-29 weeks of gestational age).",[69],"Bronchopulmonary Dysplasia (BPD)",[71,72,73,74,75,76,77],"BPD","preterm infant","nutrition","ARA","DHA","respiratory support","prematurity","2026-06-11",{"date":80,"type":44},"2026-06-17",{"date":82,"type":44},"2025-03-04",{"date":84,"type":22},"2027-03-01",{"name":50,"class":51},1,{"id":88,"slug":89,"hasResults":12,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":94,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":100,"conditions":101,"keywords":105,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":86},"100632557","dmd-gene-variants-and-cardiac-dysfunction-in-young-males-with-dystrophinopathies-100632557","NCT07515235","DMD Gene Variants and Cardiac Dysfunction in Young Males With Dystrophinopathies","Correlation of Pathogenic Variants in the DMD Gene With Cardiac Dysfunction in Male Children, Adolescents, and Young Adults With Dystrophinopathies: A Pilot Study","Inclusion Criteria:\n\n* Male sex\n* Age between 2 and 24 years at the time of enrollment\n* Genetically confirmed dystrophinopathy with a pathogenic or likely pathogenic variant in the DMD gene\n* Genetic confirmation based on at least one validated method, including MLPA, NGS, Sanger sequencing, array-CGH, or qPCR\n* Written informed consent from parents or legal guardians and, where applicable, consent from the participant\n\nExclusion Criteria:\n\n* Absence of a genetically confirmed diagnosis of dystrophinopathy, including:\n* diagnosis based solely on muscle biopsy without molecular confirmation of a pathogenic or likely pathogenic DMD gene variant\n* absence of a confirmed pathogenic variant in the DMD gene, even if maternal carrier status has been identified, unless repeat genetic testing confirms a pathogenic variant in the participant\n* Presence of congenital heart disease or other genetic disorders causing primary cardiomyopathy\n* Presence of other neuromuscular disorders\n* Female carriers, including both manifesting and asymptomatic carriers\n* Comorbidities that may independently affect cardiac function, such as severe arterial hypertension, diabetes mellitus, or chronic kidney disease","MALE","2 Years","24 Years",{"count":98,"type":22},65,"OBSERVATIONAL","The goal of this observational study is to investigate whether the type, location, and extent of pathogenic variants in the DMD gene are associated with cardiac dysfunction in male children, adolescents, and young adults with dystrophinopathies. The study also evaluates whether cardiac biomarkers and electrocardiographic findings can facilitate the early identification of cardiac involvement. Participants will undergo electrocardiography, blood sampling for cardiac biomarker assessment, and transthoracic echocardiography, with cardiac dysfunction evaluated using ejection fraction (EF) and global longitudinal strain (GLS).",[102,103,104],"Duchenne Muscular Dystrophy (DMD)","Becker Muscular Dystrophy","Cardiomyopathy",[106,107,108,109,110,111,112,113,114],"DMD gene","Non-HDL Cholesterol","NT-proBNP","Dystrophinopathy","Duchenne muscular dystrophy","Becker muscular dystrophy","Cardiac dysfunction","Global longitudinal strain","hs-TnT","2026-03-31",{"date":117,"type":44},"2026-04-07",{"date":119,"type":44},"2026-01-26",{"date":121,"type":22},"2028-02",{"name":50,"class":51},{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":135,"conditions":136,"keywords":140,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},"100476720","miecc-versus-conventional-cardiopulmonary-bypass-in-cardiac-surgery-miecs-100476720","NCT05487612","MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS)","Minimally Invasive Extracorporeal Circulation Versus Conventional Cardiopulmonary Bypass in Patients Undergoing Cardiac Surgery (MiECS): a Randomised Controlled Trial","MiECS","Inclusion Criteria:\n\n* All patients undergoing any elective or urgent coronary artery bypass grafting (CABG), aortic valve replacement (AVR) or CABG+AVR surgery using extracorporeal circulation without circulatory arrest.\n\nExclusion Criteria:\n\n* Requirement for emergency or salvage operation.\n* Requirement for major aortic surgery (e.g. aortic root replacement).\n* Contraindication or objection (e.g. Jehovah's Witnesses) to transfusion of blood products.\n* Congenital or acquired platelet, red cell or clotting disorders (patients with iron deficient anaemia will not be excluded).\n* Inability to give informed consent for the study (e.g. learning or language difficulties).","85 Years",{"count":133,"type":22},1300,[25],"MiECS is one of the largest multicentre randomised controlled trials on extracorporeal circulation conducted under the auspices of Minimal Invasive Extracorporeal Technologies International Society (MiECTiS). It is designed to ultimately address the emerging effectiveness of MiECC systems in the light of modern perfusion practice worldwide. The primary hypothesis is that MiECC, as compared to conventional CPB (cCPB), reduces the proportion of patients experiencing serious perfusion-related postoperative morbidity after cardiac surgery. The study will be led by the Clinical Research Unit of the Special Unit for Biomedical Research and Education (SUBRE), Aristotle University of Thessaloniki School of Medicine in Greece (AUSoM) with Chief Investigator Professor Kyriakos Anastasiadis, who is a key-opinion-leader in the field of MiECC, founder and Executive Board of MiECTiS.",[137,138,139],"Coronary Artery Disease","Aortic Valve Stenosis","Extracorporeal Circulation; Complications",[141,142,143,144,145],"Cardiopulmonary bypass","Extracorporeal circulation","Minimal invasive extracorporeal circulation","Coronary artery bypass grafting","Aortic valve replacement","2026-03-27",{"date":148,"type":44},"2026-03-30",{"date":150,"type":44},"2022-05-26",{"date":152,"type":22},"2029-03-31",{"name":50,"class":51},13,{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":162,"sex":17,"minAge":95,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":86},"100630146","biomarkers-of-acute-organ-injury-in-pediatric-newly-diagnosed-type-1-diabetes-100630146","NCT07483879","Biomarkers of Acute Organ Injury in Pediatric Newly Diagnosed Type 1 Diabetes","Evaluation of Biomarkers and Clinical Parameters of Acute Organ Injury in Children With Newly Diagnosed Type 1 Diabetes: The Effect of Diabetic Ketoacidosis","Inclusion Criteria:\n\n* Children aged 2-16 years\n* Newly diagnosed type 1 diabetes mellitus\n* Hospital admission for initial evaluation and treatment\n* Presence or absence of diabetic ketoacidosis at diagnosis\n* Written informed consent from parents or legal guardians\n\nFor control group:\n\n\\- Age-matched healthy children without diabetes\n\nExclusion Criteria:\n\n* Previous diagnosis of diabetes mellitus\n* Known chronic kidney disease\n* Known cardiovascular disease\n* Acute infection or inflammatory condition unrelated to diabetes\n* Use of medications that may affect renal or cardiac biomarkers",true,"16 Years",{"count":165,"type":22},45,"Diabetic ketoacidosis (DKA) is a severe metabolic complication in children with newly diagnosed type 1 diabetes mellitus (T1DM) and may be associated with early injury of vital organs such as the kidneys and the heart. Early detection of organ dysfunction is important for identifying children at increased risk for complications.\n\nThis observational cross-sectional study aims to evaluate biomarkers of acute organ injury and associated clinical and echocardiographic parameters in children with newly diagnosed T1DM presenting with DKA, compared with children with newly diagnosed T1DM without DKA and healthy controls. Biomarkers including KIM-1, NGAL, high-sensitivity troponin, NT-proBNP, interleukin-6, and C-reactive protein will be measured during hospital admission and within the first 24-48 hours of hospitalization.",[168,169],"Type 1 Diabetes Mellitus","Diabetic Ketoacidosis",[171,172,173,174,108,175,176,177,178],"Biomarkers","Acute Kidney Injury","Cardiac Biomarkers","NGAL","hs-Troponin","Pediatric Type 1 Diabetes","Myocardial Strain Imaging","KIM-1","2026-03-17",{"date":181,"type":44},"2026-03-19",{"date":183,"type":44},"2025-06-13",{"date":185,"type":22},"2030-03",{"name":50,"class":51},{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":195,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":197,"conditions":198,"keywords":202,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":86},"100584490","a-prospective-single-center-observational-study-aiming-to-assess-the-predictive-role-of-flow-mediated-dilatation-in-acute-coronary-syndromes-combined-with-echocardiographic-and-biochemical-indices-100584490","NCT06890013","A Prospective, Single-center, Observational Study Aiming to Assess the Predictive Role of Flow Mediated Dilatation in Acute Coronary Syndromes, Combined With Echocardiographic and Biochemical Indices","Identifying the Role of Flow Mediated Dilatation Assessment in Acute Coronary Syndromes - Evaluation of the Cor-IS Technology (the FLARE-ACS Trial)","FLARE-ACS","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Patients hospitalized due to acute coronary syndrome (STEMI, NSTEMI)\n3. Capability of providing written informed consent\n4. Patients able to comply with the follow-up schedule of the study\n\nExclusion Criteria:\n\n1. Patients with acute coronary syndromes classified as MINOCA, or type II myocardial infarction\n2. Patients with rare acute coronary syndrome types, such as spontaneous coronary artery dissection or Takotsubo syndrome\n3. Patients with congenital heart disease\n4. Age \\> 85 years\n5. Patients with end stage chronic kidney disease\n6. Patients with active malignancy or autoimmune diseases which limit their survival\n7. Patients with expected survival \\\u003C 1 year due to other reasons\n8. Suboptimal echocardiographic windows\n9. Inability to provide written consent\n10. Inability to comply with the follow-up schedule of the study\n11. Pregnancy\n12. Use of intravenous drugs",{"count":196,"type":22},100,"A prospective, single-center, observational study aiming to assess the predictive role of flow mediated dilatation in acute coronary syndromes, combined with echocardiographic and biochemical indices. The novel Cor-IS technology will also be evaluated.",[199,200,201],"Acute Coronary Syndromes","Flow Mediated Dilation","Endothelial Function (FMD)",[203,204,205,206],"acute coronary syndrome","endothelial dysfunction","biomarker","flow mediated dilatation","2026-02-27",{"date":209,"type":44},"2026-03-02",{"date":211,"type":44},"2024-06-01",{"date":213,"type":22},"2026-11-01",{"name":50,"class":51},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":221,"targetDuration":223,"studyType":99,"phases":4,"briefSummary":224,"conditions":225,"keywords":231,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":246},"100624720","investigation-of-preoperative-factors-influencing-the-outcome-of-motor-deficits-in-patients-undergoing-lumbar-microdiskectomy-100624720","NCT07413302","Investigation of Preoperative Factors Influencing the Outcome of Motor Deficits in Patients Undergoing Lumbar Microdiskectomy","Inclusion Criteria:\n\n* Patients suffering from lower limb paresis (motor deficit) caused by lumbar disk herniation undergoing a single-level microdiskectomy\n* Age (years) \\> 17\n\nExclusion Criteria:\n\n* Age (years) \\\u003C 18\n* Medical history of lumbar spine surgery\n* Absence of limb paresis\n* Motor deficit caused by other than disk herniation aetiologies\n* Reoperation within 6 months after microdiskectomy\n* Microdiskectomy at more than one level\n* Cauda equina syndrome\n* Peripheral neuropathy",{"count":222,"type":22},40,"6 Months","Lumbar disc herniations may result in lower limb weakness. In such cases, there is a strong indication for surgical intervention through microdiscectomy. This clinical study aims to investigate preoperative factors that may influence the postoperative outcomes of patients undergoing this procedure.",[226,227,228,229,230],"Motor Deficits","Lumbar Discectomy","Muscle Weakness","Paresis","Lumbar Disc Herniation",[232,233,234,235,236,237],"microdiscectomy","lumbar disc herniation","motor deficit","lower limb paresis","prognostic factors microdiscectomy","disc herniation outcome","2026-02-09",{"date":240,"type":44},"2026-02-17",{"date":242,"type":44},"2024-07-03",{"date":244,"type":22},"2026-12",{"name":50,"class":51},3,{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":255,"minAge":18,"maxAge":131,"enrollmentInfo":256,"targetDuration":4,"studyType":23,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":262,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":4},"100622350","neoadjuvant-chemotherapy-with-kelim-guided-interval-vs-delayed-interval-debulking-surgery-100622350","NCT07382479","NeoAdjuvant ChemoTherapy With KELIM Guided Interval vs. Delayed Interval Debulking Surgery","A Prospective, International, Multi-center, Interventional Trial of Advanced Epithelial Ovarian Cancer Patients Offered Three Cycles of Neoadjuvant Chemotherapy (NACT) and Triaged With KELIM Score. Patients With Favorable Score Will Undergo Interval Debulking Surgery (IDS) Followed by Another 3 Cycles of NACT, While Those With Unfavorable Will Undergo Another 3 Cycles of NACT Followed by Delayed Interval Debulking Surgery (DIDS).","NACT-KELIM ID","Inclusion Criteria:\n\n* Age 18 - 85 years old\n* Histologically proven epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma, high grade serous or endometrioid\n* ECOG Performance status 0 - 1\n* Documented International Federation of Gynecologic Oncology (FIGO) 2014 stage IIIB, IIIC or IVA unfit and\u002For with unresectable disease for complete primary debulking surgery (preferably triaged by \"Fagotti\" diagnostic laparoscopy)\n* HIPEC is an option after IDS or DIDS\n* Sufficiently good bone marrow, liver, and renal function to receive chemotherapy and subsequently undergo surgery\n\nExclusion Criteria:\n\n* Pregnancy\n* Synchronous malignancies at the time of diagnosis or in the 3 years prior to starting the study treatment\n* Comorbidities that may contraindicate surgery or chemotherapy as planned per protocol\n* Mucinous, clear-cell, carcinosarcoma or low-grade serous adenocarcinoma histological subtypes\n* Stable disease or progression of disease (preferably triaged by \"Fagotti\" diagnostic laparoscopy) after 6 cycles of NACT, before DIDS.","FEMALE",{"count":257,"type":22},485,[25],"A prospective, international, multi-center, interventional trial of advanced epithelial ovarian cancer patients offered three cycles of neoadjuvant chemotherapy (NACT) and triaged with KELIM score. Patients with favorable score will undergo interval debulking surgery (IDS) followed by another 3 cycles, while those with unfavorable score will undergo another 3 cycles of NACT followed by delayed interval debulking surgery (DIDS).",[261],"Ovarian Cancer","NOT_YET_RECRUITING","2026-02-03",{"date":265,"type":44},"2026-02-05",{"date":267,"type":22},"2026-04-01",{"date":269,"type":22},"2034-04-01",{"name":50,"class":51},{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":162,"sex":255,"minAge":18,"maxAge":131,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":281,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":262,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":286,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":4},"100622152","moducare-versus-wait-and-see-approach-for-histologically-proven-low-grade-cervical-intraepithelial-neoplasia-cin1-100622152","NCT07379905","MODUCARE Versus Wait-and-See Approach for Histologically Proven Low-grade Cervical Intraepithelial Neoplasia (CIN1)","A Randomized Trial of MODUCARE Versus Wait-and-See Approach for Histologically Proven Low-grade Cervical Intraepithelial Neoplasia (CIN1)","MODUCIN1","Inclusion Criteria:\n\n* Histologically proven CIN1\n* Any HPV status (negative, positive: high or low risk)\n* Any Pap test result\n* Age 18 - 85 years old\n* ECOG Performance status 0 - 1\n\nExclusion Criteria:\n\n* Pregnancy\n* Low likelihood of patient compliance to treatment protocol and follow-up\n* Previous operation to the cervix\n* Previous pelvic malignancy\n* Pre-existing histologically proven CIN1 \\> 12 months\n* Pre-existing histologically proven CIN2 and\u002For CIN3\n* Hypersensitivity to trial medication",{"count":280,"type":22},182,[25],"MODUCIN-1 (MODUcare for CIN1) is a prospective, single center, open-label, randomized trial that its purpose is to compare MODUCARE versus Wait-and-See Approach for the regression rate of histologically proven low-grade Cervical Intraepithelial Neoplasia (CIN1).",[284,285],"Low-grade Cervical Intraepithelial Neoplasia","Moducare",{"date":265,"type":44},{"date":288,"type":22},"2026-03-01",{"date":290,"type":22},"2028-03-01",{"name":50,"class":51},{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":255,"minAge":18,"maxAge":300,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":304,"conditions":305,"keywords":309,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":52},"100556317","phase-4-effect-of-a-gnrh-analog-on-hepatic-steatosis-100556317","NCT06523530","Effect of a GnRH Analog on Hepatic Steatosis","Effect of the Pharmacological Cessation of Menstruation With a GnRH Analog on Hepatic Steatosis in Women With Endometriosis","EndomMASLD","Inclusion Criteria:\n\n* women of reproductive age\n* diagnosis of endometriosis. The disease is suspected by patient's individual history (chronic pelvic pain, dyspareunia or\u002Fand dysmenorrhea) and the ultrasonographic imaging (chocolate cysts). The diagnosis is confirmed histologically, after laparoscopic surgical treatment and biopsy sampling, which will be interpreted by an independent blinded pathologist.\n* use of contraceptives, which is the first line treatment, is contraindicated or the patient does not consent to receive contraceptives, due to personal preferences.\n* written informed consent to participate to the study\n\nExclusion Criteria:\n\n* mean ethanol consumption \\>10 g\u002Fday\n* history of other chronic liver disease (e.g., viral hepatitis, autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis and overlap syndromes, drug-induced liver injury, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency)\n* liver cirrhosis\n* any malignancy\n* chronic kidney disease\n* uncontrolled hypothyroidism or hyperthyroidism\n* severe sexual hormone disorders (congenital adrenaline hyperplasia, Down syndrome, Turner syndrome).\n* use of the following medications within a 12-month period before baseline, which are associated with drug-induced liver injury (DILI): interferon, tamoxifen, amiodarone, aloperidin, glucocorticoids, hormone replacement therapy, contraceptives, anabolic steroids, any medication against tuberculosis, epilepsy or viruses, methotrexate, parenteral nutrition\n* use of the following medications within a 12-month period before baseline, which are probably associated with improvement in hepatic steatosis: vitamin E, pioglitazone, insulin, glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium- glucose co-transporter-2 inhibitors (SGLT-2i), orlistat, ursodeoxycholic acid\n* use of any GnRH agonist or antagonist within a 12-month period before baseline","45 Years",{"count":302,"type":22},62,[66],"Menopause increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD), possibly owing to the abrupt lack of estrogen. Gonadotropin-releasing hormone (GnRH) treatment in endometriosis is regarded as a model of pharmaceutical menopause. Thus, the effect of goserelin acetate, a GnRH analog that results in transient menopause, on hepatic steatosis and fibrosis will be evaluated in this study.",[306,307,308],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Nonalcoholic Fatty Liver","Endometriosis",[310,311,312,313,314,315,316,317,318,319,320,321,322],"endometriosis","goserelin acetate","hepatic fibrosis","MASLD","MASH","metabolic dysfunction-associated steatotic liver disease","metabolic dysfunction-associated steatohepatitis","NAFLD","NASH","nonalcoholic fatty liver disease","nonalcoholic steatohepatitis","treatment","menopause","2026-02-01",{"date":263,"type":44},{"date":326,"type":44},"2024-11-26",{"date":328,"type":22},"2027-10",{"name":50,"class":51},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":255,"minAge":18,"maxAge":337,"enrollmentInfo":338,"targetDuration":4,"studyType":23,"phases":340,"briefSummary":341,"conditions":342,"keywords":345,"overallStatus":262,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":52},"100618699","the-role-of-follicular-flushing-at-oocyte-retrieval-100618699","NCT07335016","The Role of Follicular Flushing at Oocyte Retrieval","FOFLOR","Inclusion Criteria:\n\n* Ovarian stimulation with recFSH and GnRH antagonist or PPOS protocol\n* Triggering final oocyte maturation with hCG or GnRH agonist\n* The day of oocyte retrieval at least one follicle of mean diameter of 11mm in each ovary\n* ICSI method of fertilisation.\n\nExclusion Criteria:\n\n* Presence of ovarian cyst of endometriosis\n* History of ovarian surgery\n* Monofollicular growth\n* Presence of only one ovary\n* Ovary not accessible at oocyte retrieval","46 Years",{"count":339,"type":22},75,[25],"In vitro fertilization (IVF) is the most common method of medically assisted reproduction, involving fertilization of the egg by sperm in a lab. The process includes ovarian stimulation, oocyte retrieval, fertilization and culture, and embryo transfer. The success of IVF depends mainly on female age-as age increases, ovarian reserve and oocyte quality decrease-and the number of oocytes retrieved.\n\nThis study investigates whether follicular flushing during oocyte retrieval can increase the number of mature oocytes retrieved. This randomized study will be conducted in women undergoing ovarian stimulation with recombinant Folicullar Stimulating Hormone (FSH) and Gonadotropin-Releasing Hormone (GnRH) antagonist or Progestin Primed Ovarian Stimulation (PPOS) to suppress premature Luteinizing hormone (LH) rise. Final oocyte maturation will be triggered with recombinant Human chorionic gonadotropin (hCG) or GnRH agonist.\n\nEligible participants will have at least one follicle ≥11 mm in each ovary. On the day of oocyte retrieval, one ovary will be randomized to undergo follicular flushing using a single-lumen needle and the other simple aspiration, using the same needle. All fertilized oocytes from both ovaries will be cultured, seperately, to the blastocyst stage.\n\nStudy outcomes are the number of oocytes and mature oocytes retrieved, the oocyte retrieval rate, the mature oocyte retrieval rate, the maturation rate, the number of fertilized oocytes, the fertilisation rate, the number of blastocytes and the blastulation rate.\n\nSample size of 75 patients (25 per response category: poor, normal, high) provides 82-98% power to detect clinically meaningful interaction effects (Cohen's f=0.19-0.34) between response category and technique (follicular flushing vs. simple aspiration) under conservative assumptions of 50-70% of pilot study effects, lower correlations (ρ=0.35), and increased variability (α=0.05, two-sided, 5% attrition buffer.",[343,344],"Infertility (IVF Patients)","Oocyte Retrieval for IVF",[346,347,348],"ivf","follicular flushing","oocyte retrieval","2026-01-11",{"date":351,"type":44},"2026-01-13",{"date":353,"type":22},"2026-01-14",{"date":355,"type":22},"2029-01-20",{"name":50,"class":51},{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":23,"phases":366,"briefSummary":367,"conditions":368,"keywords":372,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":86},"100615165","positive-psychology-for-early-cognitive-decline-effects-on-cognitive-and-brain-function-100615165","NCT07289061","Positive Psychology for Early Cognitive Decline: Effects on Cognitive and Brain Function","Application of Positive Psychology Interventions in Individuals With Early-stage Cognitive Decline Related to Dementia: Their Impact on Cognitive and Brain Functioning","Inclusion Criteria\n\n-Documented diagnosis of Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI) according to clinical evaluation and site standard criteria.\n\nExclusion Criteria\n\n* Diagnosis of dementia (major neurocognitive disorder) or other major neurocognitive disorder that is moderate or severe.\n* Major psychiatric disorder currently unstable or untreated (e.g., major depression with psychotic features, bipolar disorder, schizophrenia).\n* Neurological conditions that affect cognition.\n* Uncorrected hearing or vision problems that prevent participation in assessments or online sessions.\n* Concurrent participation in another interventional study targeting cognition or wellbeing during the study period.",{"count":365,"type":22},128,[25],"This randomized study tests whether a new multicomponent Positive Psychology program can improve cognition and wellbeing in older adults at the earliest stages of dementia-related decline.\n\nAbout 128 participants with Subjective Cognitive Decline or Mild Cognitive Impairment will be enrolled. Half will be randomized to the Positive Psychology program and half to Treatment As Usual (TAU).\n\nThe program consists of weekly, small-group online sessions for \\~24 weeks plus brief home practices. All participants (both arms) will complete questionnaires and cognitive tests at baseline, during treatment, post-treatment, and 9-month follow-up.\n\nPrimary question: Do participants receiving the Positive Psychology program show better cognitive and brain-function outcomes than TAU at post-treatment and at 9 months? Secondary question: Are effects larger for SCD than MCI? No medicines are used and risks are minimal. If effective, this scalable, low-cost, non-pharmacological approach could complement usual care for people in very early cognitive decline.",[369,370,371],"Subjective Cognitive Decline (SCD)","Mild Cognitive Impairment (MCI)","Alzheimer Dementia (AD)",[373,374,375,376,377,378,379,380],"positive psychology","non-pharmacological intervention for dementia","character strengths","mindfulness","forgiveness","gratitude","humor","alzheimer's disease","2026-01-06",{"date":383,"type":44},"2026-01-07",{"date":385,"type":44},"2025-12-17",{"date":387,"type":22},"2027-07",{"name":50,"class":51},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":162,"sex":17,"minAge":395,"maxAge":131,"enrollmentInfo":396,"targetDuration":398,"studyType":99,"phases":4,"briefSummary":399,"conditions":400,"keywords":403,"overallStatus":262,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":86},"100615785","validation-of-the-montreal-cognitive-assessment-moca-version-8x-and-moca-mis-in-greece-100615785","NCT07297121","Validation of the Montreal Cognitive Assessment (MoCA) Version 8.x and MoCA-MIS in Greece.","Inclusion Criteria:\n\n* Participants between the ages of 55-85\n* Fluent in Greek to avoid misunderstandings during the assessment\n* Participants must be able to provide informed consent\n\nExclusion Criteria:\n\n* History of severe psychiatric or neurological disorders apart from MCI\u002Fdementia\n* Patients having acute medical illnesses\n* Patients having severe hearing and\u002For visual impairments","55 Years",{"count":397,"type":22},250,"4 Weeks","Objective: The purpose of this study is to assess the psychometric qualities of the Montreal Cognitive Assessment (MoCA) version 8.x in Greek, including the MoCA-MIS. We intend to examine the tool's reliability (internal consistency, test-retest reliability) and validity (construct validity, concurrent validity, and known-group validity).\n\nAim: The findings will support the tool's application for early cognitive impairment identification in clinical and research settings.",[401,402,370],"MCI","Dementia",[401,404,405,406,407,408,409,410],"MoCA","MoCA-MIS","Validation","Mild Cognitive Impairment","screening","dementia","memory testing","2025-12-09",{"date":413,"type":44},"2025-12-22",{"date":415,"type":22},"2026-01-01",{"date":417,"type":22},"2027-06-01",{"name":50,"class":51},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":427,"enrollmentInfo":428,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":429,"conditions":430,"keywords":432,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":86},"100615532","impact-of-cardio-selective-beta-blockers-on-infarct-size-after-acute-myocardial-infarction-100615532","NCT07293832","Impact of Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction","The Impact of Sympathetic Drive Control With Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction","BLOCK-AMI","Inclusion Criteria:\n\n* Age between 18 and 80 years\n* Patients with electrocardiogram showing ST-segment elevation ≥2 mm in 2 or more contiguous leads for more than 30 minutes\n* Estimated time from symptom onset to reperfusion ≤12 hours\n* Patients scheduled to undergo primary angioplasty\n* Patients who have signed a consent form\n\nExclusion Criteria:\n\n* Patients receiving chronic medication with beta-adrenergic blockers\n* Patients with a previous myocardial infarction\n* Persistent systolic blood pressure \\\u003C90 mmHg\n* Persistent heart rate \\\u003C55 beats per minute\n* Patients with Killip class III (acute pulmonary edema) or IV (cardiogenic shock) on initial examination\n* 12-lead electrocardiogram with PR interval \\>200 milliseconds\n* 12-lead electrocardiogram showing second- or third-degree atrioventricular block\n* Bronchospasm requiring bronchodilator treatment\n* Possible pregnancy or postpartum period\n* Inability or refusal to sign the consent form","80 Years",{"count":196,"type":22},"Introduction: The effect of intravenous beta-blockers on the extent of the necrotic area, after primary percutaneous transluminal coronary angioplasty (PTCA), for acute myocardial infarction is not well established.\n\nPurpose: The present study aims to investigate, whether the early intravenous administration of landiolol, a highly cardioselective b-blocker, reduces the extent of the necrotic area after ST-elevation myocardial infarction (STEMI).\n\nMethods: This prospective observational cohort study will enroll patients presenting with STEMI, who undergo primary PCI and receive either intravenous landiolol or standard oral β-blocker therapy, in accordance with current European Society of Cardiology (ESC) guidelines. Eligibility will be determined by predefined inclusion and exclusion criteria. Treatment selection will be based solely on the clinical judgment of the attending cardiologist, without randomization.\n\nResults: Final infarct size will be quantified by cardiac magnetic resonance imaging (CMR) performed at least three months after the STEMI to minimize edema-related overestimation. Myocardial function will be assessed during hospitalization using transthoracic echocardiography, including measurement of global longitudinal strain (GLS). Additional data will include serial high-sensitivity troponin and creatine phosphokinase (CPK) measurements, 24-hour continuous electrocardiographic monitoring for arrhythmia burden, and predefined safety outcomes collected throughout hospitalization.",[431],"STEMI",[433],"beta-blocker","2025-12-07",{"date":436,"type":44},"2025-12-19",{"date":438,"type":44},"2024-11-13",{"date":440,"type":22},"2026-08",{"name":50,"class":51},{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":255,"minAge":18,"maxAge":131,"enrollmentInfo":450,"targetDuration":4,"studyType":23,"phases":451,"briefSummary":452,"conditions":453,"keywords":465,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":86},"100609100","pre-habilitation-within-eras-protocol-for-gynecologic-oncology-surgery-the-preeras-study-100609100","NCT07210164","Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study","Prehabilitation With Exercise and Immunonutrition (Ocoxin®) in the Perioperative Management of Gynecologic Malignancies Under ERAS Protocol.","Pre_ERAS","Inclusion Criteria:\n\n* Type of gynecological malignancy: endometrial cancer, ovarian cancer, cervical cancer, treated with laparotomy after the decision of the gynecological-oncology unit (positive opinion of the Multidisciplinary Tumor Board - MDT)\n* Patient age: 18 to 85 years\n* General condition of the patient: ASA score I-III\n* Consent to implement the accelerated recovery protocol - Enhanced recovery after surgery (ERAS)\n* Sufficient understanding of the Greek language\n* Provision of signed, after thorough information, consent to participate in the study\n\nExclusion Criteria:\n\n* Women with performance status: ECOG \\>2 and ASA score \\>III\n* Women who have not been informed and have given written consent",{"count":196,"type":22},[25],"ERAS (Enhanced Recovery After Surgery) protocols are step-by-step care plans that help patients recover faster after surgery. They focus on keeping the body's normal functions, lowering stress from surgery, and supporting a quicker recovery. In gynecologic cancer surgeries, ERAS has been shown to help patients do better, have fewer problems, and leave the hospital sooner.\n\nA prehabilitation program, in combination with ERAS protocols, aims to optimize patients' physical and psychological condition prior to surgery for gynecological cancers. Interventions may include tailored exercise, nutritional support, respiratory training, and psychological preparation. By enhancing baseline fitness and resilience, prehabilitation improves the body's ability to tolerate surgical stress, reduces complications, and facilitates a faster, smoother recovery within the ERAS framework.",[454,455,456,457,458,459,460,461,462,463,464],"ERAS","Compliance","Quality of Life (QOL)","Excercise","Immunonutrition","Post Operative Pain","Laparotomy Patients","Surgical Complication","Gynaecological Malignancies","Gynaecologic Cancer","Gynaecological Oncology",[466,454,467,458],"Prehabilitation","Gynecologic Cancers","2025-09-29",{"date":470,"type":44},"2025-10-07",{"date":472,"type":22},"2025-12-01",{"date":474,"type":22},"2029-12-30",{"name":50,"class":51},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":482,"eligibilityCriteria":483,"healthyVolunteers":162,"sex":17,"minAge":484,"maxAge":398,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":486,"briefSummary":487,"conditions":488,"keywords":491,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":52},"100604543","lactase-assisted-control-trial-on-weight-gain-in-infants-100604543","NCT07150884","Lactase-Assisted Control Trial On Weight GAin in INfants.","A Randomized, Double-blind, Patient-control Trial to Study Weight Gain in Premature Newborns Receiving Lactase-fortified Milk","LACTOGAIN","Inclusion Criteria:\n\nThe study will enrol newborns (1) with a gestational duration of 28 to 34 weeks, (2) who receive ≥75% of their energy needs intestinally, (3) with the absence of severe congenital malformations or gastrointestinal diseases, including necrotizing enterocolitis (NEC) (4) without taking postnatal steroids or diuretics. Small, suitable and large for newborns of gestational age will be eligible for the study.\n\nExclusion Criteria:\n\nExclusion criteria will be neonates whose guardians refuse to participate in the study, neonates with congenital malformations or gastrointestinal diseases, and neonates receiving postnatal steroids or diuretics.","1 Day",{"count":196,"type":22},[25],"Lactose, a disaccharide that includes the monosaccharides glucose and galactose, is the main carbohydrate found exclusively in mammalian milk. Lactase is found in the intestinal mucosa and is located at the ends of the villi, while it is a factor of maximum clinical importance in milk tolerance and in the occurrence of diarrheal disease. Developmental lactase deficiency is defined as the relative lactase deficiency observed in premature newborns less than 34 weeks of gestation. In the immature gastrointestinal tract, lactase and other disaccharidas are deficient until at least 34 weeks of gestation. One study in premature babies reported a benefit from the use of lactase-supplemented or lactose-reduced formulas, while the use of lactose-containing formulas and human milk did not appear to have short- or long-term harmful effects on infants and infants. Up to 20% of dietary lactose can reach the colon in newborns and young infants.\n\nDue to the inadequate functional development of lactase, premature infants may not digest and absorb the main source of carbohydrate energy, lactose. The high osmotic load associated with indigestible lactose is one of the many possible causes of diarrhea and food intolerance in premature babies. As a result of diarrhea stools and small bowel damage, the already low functional activity of lactase will be further reduced affecting weight gain, while it takes up to 2 weeks for lactase activity to be restored.\n\nCarlson et al showed that the addition of lactase to premature formula reduces the amount of lactose by 70%, with a negligible effect on osmolarity. Previous studies have found that premature infants fed a reduced lactose formula had a better weight gain rate than those who took 100% lactose formula. In two of these studies, weight gain improved despite eating fewer calories.\n\nIn the present study we intend to test whether the use of lactase to hydrolysis lactose in premature milk would result in better weight gain and improved dietary tolerance by taking the same calorie intake. This is a prospective, double-blind, randomized study to evaluate tolerance and weight gain in premature infants who received either (1) human milk or premature formula enriched with Delictase ® drops (lactase group) or (2) unfortified human milk or premature formula (control group).\n\nThe study will be carried out at the Second Neonatal Clinic and Neonatal Intensive Care Unit of the Aristotle University of Thessaloniki, in premature newborns (gestational age \\[GA\\] 28-34 weeks) who will be hospitalized in the Neonatal Intensive Care Unit.\n\nThe study will enroll newborns (1) with a gestational duration of 28 to 34 weeks, (2) who receive ≥75% of their energy needs intestinally, (3) with the absence of severe congenital malformations or gastrointestinal diseases, including necrotizing enterocolitis (NEC) (4) without taking postnatal steroids or diuretics. Small, suitable and large for newborns of gestational age will be eligible for the study.\n\nExclusion criteria will be neonates whose guardians refuse to participate in the study, neonates with congenital malformations or gastrointestinal diseases, and neonates receiving postnatal steroids or diuretics.\n\nThe participation of newborns in the study will take place after written consent of the parents after information.",[489,490],"Premature - Weight 1000g-2499g or Gestation of 28-37weeks","Healthy",[492,493,494,495,496],"Lactase","Prematurity","Human milk","Weight gain","Feeding intolerance","2025-09-09",{"date":499,"type":44},"2025-09-11",{"date":501,"type":44},"2025-08-27",{"date":503,"type":22},"2027-08",{"name":50,"class":51},{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":511,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":513,"targetDuration":4,"studyType":23,"phases":515,"briefSummary":516,"conditions":517,"keywords":4,"overallStatus":262,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":521,"completionDateStruct":522,"leadSponsor":524,"locationsCount":4},"100605485","tragus-stimulation-for-pots-treatment-100605485","NCT07163130","Tragus Stimulation for POTS Treatment","Transcutaneous Auricular Vagus Nerve Stimulation in Postural Tachycardia Syndrome: a Prospective Cross-over Study","TREAT-POTS","Inclusion Criteria:\n\n* Male or female patients aged ≥18 years\n* Diagnosis of POTS, defined as heart rate increase \\>30 beats\u002Fmin from supine within 10 minute of standing, in the absence of orthostatic hypotension (\\>20\u002F10 mm Hg fall in blood pressure), with chronic symptoms (\\>6 months), and in the absence of other acute causes of orthostatic tachycardia,\n* Signed written informed consent by the patient for participation in the study and agreement to comply with the study procedures and the follow-up schedule.\n\nExclusion Criteria:\n\n* Hypertension (\\>150 mmHg systolic and \\>100 mmHg diastolic) based on history or findings at screening.\n* Orthostatic hypotension (consistent drop in blood pressure \\>20\u002F10 mmHg with 10 min of standing)\n* History or presence of significant neurological, immunological, or hematological disorders\n* Cardiovascular disease, such as myocardial infarction within 6 months\n* Patients on renal dialysis.\n* Life expectancy of \\\u003C12 months\n* Currently pregnant women or women planning on becoming pregnant ≤ 5 months\n* Patients with active implants (such as a cardiac pacemaker, implantable cardioverter-defibrillator, or a cochlear implant)\n* Known channelopathy such as Brugada syndrome, long QT syndrome, or Catecholaminergic monomorphic ventricular tachycardia.\n* Episodic or permanent complete heart block or 2nd degree atrioventricular block Mobitz 2 or bifascicular block with concurrent 1st degree atrioventricular block\n* Congestive heart failure New York Heart Association class IV, defined as shortness of breath at rest, which is refractory to medical treatment (not responding to treatment)\n* Inability to comply with the protocol.",{"count":514,"type":22},24,[25],"Postural Tachycardia Syndrome (POTS) is a form of dysautonomia characterized by an abnormal cardiovascular response to orthostatic challenges. Individuals afflicted with POTS typically exhibit a heart rate increase of more than 30 beats per minute (bpm) within 10 minutes of assuming an upright posture from a supine or sitting position. This abnormal response is often accompanied by symptoms, such as orthostatic intolerance, dizziness, weakness, fatigue, and, in certain instances, syncope. Lately, there is revived interest in POTS, as it has been quite frequently reported as a manifestation of autonomic dysfunction among patients with long COVID. POTS primarily affects the younger demographic, particularly women, and its pathophysiology appears to be multifactorial, involving autonomic neuropathy, hyperadrenergic state, and inadequate blood volume regulation. Diagnostic criteria commonly include a sustained heart rate increase without significant orthostatic hypotension. The pathophysiological mechanisms of POTS are complex and not fully elucidated. Management strategies encompass lifestyle modifications, exercise programs, and pharmacotherapy, but their efficacy is modest.\n\nTranscutaneous auricular vagus nerve stimulation (tVNS) is an emerging therapeutic modality in cardiovascular diseases. tVNS has been shown to exert antiadrenergic and anti-inflammatory effects in humans. Recently, tVNS has been tested in experimental and human POTS, leading to improved autonomic function, reduction of anti-autonomic autoantibodies and inflammatory cytokines. However, the exact patient characteristics that would identify a patient likely to respond to tVNS as well as further mechanistic and clinical endpoints with tVNS have not been explored.\n\nThe aim of this study is to assess and characterize in detail the effect of tVNS in patients with POTS. This is a prospective crossover study in patients with POTS. The expected study duration is approximately 15 months from the time the first subject is enrolled to study termination. Patient enrollment is planned to take place at 3-4 major centers in Greece.",[518],"Postural Orthostatic Tachycardia Syndrome (POTS)","2025-09-01",{"date":497,"type":44},{"date":519,"type":22},{"date":523,"type":22},"2027-01-31",{"name":50,"class":51},{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":531,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":427,"enrollmentInfo":533,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":534,"conditions":535,"keywords":537,"overallStatus":262,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":548,"locationsCount":4},"100605271","translation-and-validation-of-the-hypoparathyroidism-patient-experience-scales-hpes-questionnaire-in-greek-100605271","NCT07160348","Translation and Validation of the Hypoparathyroidism Patient Experience Scales (HPES) Questionnaire in Greek","Translation and Validation of the Hypoparathyroidism Patient Experience Scales (HPES) Questionnaire in Patients With Hypoparathyroidism for Use in the Greek Population","HPES","Inclusion Criteria:\n\nPatients should be ≥18 years of age, fluent in Greek language, diagnosed with chronic HP, on optimal treatment with calcium and active vitamin D metabolites. Chronic HP is defined when continuous therapy with calcium and vitamin D is required for \\>12 months.\n\nExclusion Criteria:\n\n1. Patients inadequately controlled with conventional therapy:\n\n   1. corrected serum Ca (cCa) ≤8 mg\u002Fdl or cCa ≤8.2 mg\u002Fdl with symptoms of hypocalcemia\n   2. serum P \\>5.5 mg\u002Fdl\n2. Age \\>80 years\n3. Presence of neoplastic disease\n4. Pregnancy\n5. Diagnosis of psychiatric disease or cognitive impairment\n6. Participants experiencing other comorbidities that may affect QoL\n7. Lack of informed consent",{"count":21,"type":22},"This is a crossectional study that will be conducted at several tertiary centers in Greece.\n\nTo participate in the study, patients should be ≥18 years of age, fluent in Greek language, diagnosed with chronic HP, on optimal treatment with calcium and active vitamin D metabolites. Chronic HP is defined when continuous therapy with calcium and vitamin D is required for \\>12 months.\n\nExclusion criteria will include:\n\n1. Patients inadequately controlled with conventional therapy:\n\n   1. corrected serum Ca (cCa) ≤8 mg\u002Fdl or cCa ≤8.2 mg\u002Fdl with symptoms of hypocalcemia\n   2. serum P \\>5.5 mg\u002Fdl\n2. Age \\>80 years\n3. Presence of neoplastic disease\n4. Pregnancy\n5. Diagnosis of psychiatric disease or cognitive impairment\n6. Participants experiencing other comorbidities that may affect QoL\n7. Lack of informed consent The study will seek approval from the Ethics in Research Committee of its participating center. All participants will be informed about the objectives of the study and will sign an informed consent.\n\nThe HPES-Symptom was developed in accordance with the Food and Drug Administration guidance and best research practices for PRO measure development. The methodology used has been previously described.\n\nThe first step of the translation process requires two forward translations of the English version of the questionnaire. The translations will be done by two translators who are native speakers of the target (Greek) language and can understand the English version. Then a reconciled translation is made based on the two translations - that is, the chief investigator will review the two translations to achieve the best possible version by choosing one of the two translations or by combining them on the basis of their correctness, wording etc.\n\nThe next step requires translating the reconciled version back into English, again done by two translators who will be native speakers of English or at least will have a very good command of English.",[536],"Hypoparathyroidism",[538,539,540,541],"hypoparathyroidism","parathyroid hormone","palopegteriparatide","calcium metabolism disorders","2025-08-29",{"date":544,"type":44},"2025-09-08",{"date":546,"type":22},"2025-10-01",{"date":267,"type":22},{"name":50,"class":51},{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":23,"phases":557,"briefSummary":558,"conditions":559,"keywords":561,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":86},"100601640","effects-of-a-long-term-exercise-training-program-on-the-functional-capacity-and-health-related-quality-of-life-in-inpatients-with-psychotic-disorders-100601640","NCT07113119","Effects of a Long-term Exercise Training Program on the Functional Capacity and Health-related Quality of Life in Inpatients With Psychotic Disorders","Inclusion Criteria:\n\n* being an adult\n* inpatient with a diagnosis of psychotic syndrome\n* on stable medication\n* controlled as far as psychosis is concerned\n* consenting to participate\n\nExclusion Criteria:\n\n* adolescents\n* with other diagnoses\n* not on stable medication\n* in an unstable condition\n* unwilling to participate in the study",{"count":556,"type":22},48,[25],"Mental health represents a fundamental dimension of overall well-being, exerting a significant influence on mortality rates, health-related quality of life (HRQoL), levels of disability, and the strain on healthcare systems. As the interest in mental wellness continues to grow, exercise training (ET) has become increasingly recognized as a validated and effective intervention for individuals experiencing mental health challenges. An expanding body of research underscores the adverse effects of physical inactivity, reinforcing the role of exercise as a viable therapeutic strategy.\n\nWell-structured ET interventions have consistently demonstrated benefits across multiple domains, including improvements in physical health, reductions in cardiovascular risk, and enhancements in psychological constructs such as depression, self-esteem, resilience, and self-efficacy. However, the majority of prior studies have been limited to relatively short durations-typically ranging from 4 to 24 weeks, with an average of about 12 weeks. A significant gap in the literature persists regarding the long-term implementation and effectiveness of ET programs, particularly in populations with severe mental illness. Additionally, the small sample sizes commonly seen in previous studies restrict the statistical robustness and generalizability of their outcomes.\n\nThe aim of the randomized control trial is to examine whether an 1-year mixed type exercise training program within the hospital setting will improve functional capacity and health-related quality of life. Forty- eight participants will be randomly allocated into two groups: Group A (Exercise group) will receive 3 exercise sessions per week for 1-year and Group B (Control Group) will continue their usual care, without participating in organized exercise programs. Prior to the group random allocation, part of the assessment at the baseline and 1 year follow-up will include lower extremity strength test, muscle power using a dynamometer, aerobic capacity test, balance test, body positioning and health- related quality of life.",[560],"Psychotic Disorder",[562,563,564,565],"Exercise","Functional ability","Quality of life","Pilates","2025-08-06",{"date":568,"type":44},"2025-08-08",{"date":570,"type":44},"2024-08-04",{"date":572,"type":22},"2025-08-15",{"name":50,"class":51},{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":581,"enrollmentInfo":582,"targetDuration":4,"studyType":23,"phases":583,"briefSummary":584,"conditions":585,"keywords":587,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":86},"100518905","the-effect-of-exercise-training-and-detraining-on-frailty-and-fall-risk-in-patients-with-chronic-heart-failure-100518905","NCT06036615","The Effect of Exercise Training and Detraining on Frailty and Fall Risk in Patients With Chronic Heart Failure","The Effect of Exercise Training Intervention and Detraining on Frailty and Fall Risk in Patients With Chronic Heart Failure.","Inclusion Criteria:\n\n* Age \\> 18 yrs. of either gender\n* Confirmed diagnosis (by echocardiography) of HF reduced or preserved left ventricular ejection fraction (HFrEF\u002FΗFpEF)\n* Symptomatic New York Heart Association (NYHA) class II-III\n\nExclusion Criteria:\n\n* Acute Myocardial Infarction (\\\u003C4 weeks)\n* Severe valvular diseases\n* Potentially malignant arrhythmias\n* Νeurological, or orthopedic limitations\u002Fnon- ambulant status\n* Cognitive disorders\n* Poor regulation of comorbidities\n* Already participating in organized exercise programs\n* Current pregnancy\n* NYHA function class IV\n* Inability\u002Funwillingness to give informed consent","100 Years",{"count":196,"type":22},[25],"Chronic Heart Failure (CHF) is the endpoint for some cardiac and respiratory conditions as well as ageing affecting 1-2% of the global adult population. CHF requires a costly treatment, frequent hospitalizations due its severe complications leading CHF eventually to a frequent cause of morbidity and mortality worldwide. Another common complication of CHF is frailty. Frailty is a complex clinical syndrome associated with CHF, resulting from multiple organ impairment; physiological reserves decrease and vulnerability to stressors increase. Up to 79% of PwCHF are frail leading to reduced functional capacity, quality of life (QoL), and psychological well-being in CHF, and it is an independent predictor of mortality in cardiovascular disease.\n\nThe role of cardiac rehabilitation (CR) programs for PwCHF in preventing frailty has recently draw the attention of the scientific world. Exercise constitutes a unique effective and feasible non-pharmacological treatment for frailty in CHF as it offers such benefits that are irreplaceable by medical treatment, with no side effects, and cost-effective treatment. However, there are no studies examining the effect of training and detraining on muscle strength and balance, fall prevention and fear of falling in PwCHF.\n\nThe aim of this randomized controlled trial is to examine whether a 6-month combined aerobic, strengthening and flexibility-mobility CR program and a 3-month de-training period will affect frailty and fall risk in PwCHF. One hundred participants will be randomly allocated into two groups: Group A (Exercise Group) will receive 3 sessions per week for 6 months and Group B(Control Group) will continue their usual physical activity, without participating in organized exercise programs.After the intervention for Group A' will follow a 3- month de-training period and Group B' will continue their normal physical activity. Prior to the group random allocation, part of our assessments at baseline and after 6 (Evaluation A') and 10 months (Evaluation B'), will include demographics and clinical history, physical examination, ECG and echocardiogram, patients' ability to perform daily activities, functional tests, static balance tests, body composition analysis and 24-h heart rhythm holter monitoring. Moreover, we will use questionnaires assessing the QoL of people with CHF, depression, anxiety, sleep quality, cognitive function, fear of falling, physical activity, and sedentary behaviour.",[586],"Chronic Heart Failure",[586,588,562],"Cardiac Rehabilitation",{"date":590,"type":44},"2025-08-11",{"date":592,"type":44},"2023-10-01",{"date":594,"type":22},"2025-12-15",{"name":50,"class":51},{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":162,"sex":17,"minAge":18,"maxAge":603,"enrollmentInfo":604,"targetDuration":4,"studyType":23,"phases":606,"briefSummary":608,"conditions":609,"keywords":611,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":86},"100563945","phase-2-the-use-of-a-porcine-collagen-matrix-for-the-prevention-of-buccal-bone-wall-resorption-during-implant-placement-in-the-aesthetic-zone-100563945","NCT06622759","The Use of a Porcine Collagen Matrix for the Prevention of Buccal Bone Wall Resorption During Implant Placement in the Aesthetic Zone.","The Use of a Porcine Collagen Matrix for the Prevention of Buccal Bone Wall During Implant Placement in the Aesthetic Zone. A Randomized Controlled Clinical Trial.","Inclusion Criteria:\n\n1. Generally healthy adult patients.\n2. 18 years or older.\n3. Need for replacement of single implant in the upper aesthetic zone (second premolar to second premolar)\n4. Ridge width (bucco-lingual) no greater than 6 mm at its narrowest point.\n5. Minimum 2mm of attached gingiva.\n6. Ability to comply with the study related procedures such as exercising good oral hygiene and attending all follow-up examinations.\n7. Ability to fully understand the nature of the proposed surgery and ability to sign the informed consent form\n\nExclusion Criteria:\n\n1. Poor oral hygiene (FMPS \\\u003C 20%, FMBS \\\u003C 15%) and poor motivation\n2. Heavy smokers (\\>10 cigarettes per day)\n3. Need for bone augmentation\n4. Untreated periodontitis\n5. General contraindications for dental and\u002For surgical treatment\n6. History of malignancy, radiotherapy, or chemotherapy for malignancy within the past 5 years\n7. Women of child bearing age, not using a standard accepted method for contraception\n8. Pregnancy or breast feeding\n9. Previous and concurrent medication affecting mucosal healing in general (e.g. steroids, large doses of anti-inflammatory drugs\n10. Disease affecting connective tissue metabolism (e.g. collagenases)\n11. Allergy to collagen","75 Years",{"count":605,"type":22},36,[607],"PHASE2","Aim:\n\nTo provide a comparative assessment of the clinical and radiographic effect of porcine collagen matrix when placed buccally at the time of single implant placement in the aesthetic zone vs autogenous connective tissue graft in terms of buccal bone resorption and soft tissue augmentation 6 months post operative. Histological assessment and patient reported outcomes were reported",[610],"Soft Tissue Augmentation",[612,613,614,615,616,617,618],"Implants","Esthetic zone","Soft tissue augmentation","Collagen matrix","Soft tissue grafts","Connetive Tissue Graft","Porcine collagen matrix","2025-08-03",{"date":621,"type":44},"2025-08-07",{"date":623,"type":44},"2023-03-24",{"date":625,"type":22},"2025-08-30",{"name":50,"class":51},{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":4,"eligibilityCriteria":633,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":634,"enrollmentInfo":635,"targetDuration":4,"studyType":23,"phases":636,"briefSummary":637,"conditions":638,"keywords":643,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":648,"lastUpdatePostDateStruct":649,"startDateStruct":651,"completionDateStruct":653,"leadSponsor":655,"locationsCount":86},"100596032","comparison-of-distalization-of-maxillary-first-and-second-molars-between-a-miniscrew-implant-supported-device-and-clear-aligners-100596032","NCT07040176","Comparison of Distalization of Maxillary First and Second Molars Between a Miniscrew Implant Supported Device and Clear Aligners.","Comparison of Distalization of Maxillary First and Second Molars Between a Miniscrew Implant Supported Device and Clear Aligners: A Randomized Clinical Trial.","Inclusion Criteria:\n\n* Patients with at least half cusp bilateral Class II malocclusion between upper and lower first molars due to maxillary excess or maxillary protrusion or forward movement of the maxillary posterior teeth, where maxillary molar distalization is indicated.\n* Patients in the permanent dentition period of less than 30 years of age with second molars erupted at least one half.\n* Patients with good general health and healthy periodontium.\n\nExclusion Criteria:\n\n* Patients with Class II malocclusion between upper and lower first molars due to mandibular deficiency or mandibular retrusion.\n* Patients with less than half cusp bilateral Class II malocclusion between upper and lower first molars.\n* Patients with unilateral Class II malocclusion between upper and lower first molars.\n* Patients with cleft lip and palate or with other craniofacial syndromes.\n* Patients with missing, or congenital missing or supernumerary teeth.\n* Patients with full coverage molar restorations.\n* Patients with previous orthodontic treatment.","30 Years",{"count":222,"type":22},[25],"The goal of this randomized clinical trial is to compare distalization of maxillary first and second molars achieved with a device supported with mini screw implants in the palate (Advanced Molar Distalization Appliance, AMDA®) with distalization of maxillary first and second molars achieved with clear aligners (Spark®) supported by Class II elastics.\n\nThe main questions it aims to answer are:\n\nIs there any difference in achieving upper molar distalization with the Advanced Molar Distalization Appliance (AMDA®) supported by miniscrew implants and with clear aligners (Spark®) supported by Class II elastics at the end of active distalization phase?\n\nIs there any difference between the two groups in the anchorage loss at the end of total treatment?\n\nAdditionally, the differences in the movements of premolars, canines and incisors will be analyzed in all three planes of space (sagittal, transverse, vertical), as well as the duration of treatment between the two groups and subgroup comparisons will be performed regarding age, gender, presence of maxillary third molars and severity of malocclusion.\n\nParticipants will be randomly assigned to the AMDA® or Spark® group. Treatment will take place at the Department of Orthodontics and participants will have to visit the clinic every 4-6 weeks for regular check ups. Intraoral scans, photographs and x-rays (panoramic x-ray, cephalometric x-rays) will be taken before treatment, at the end of active distalization phase and at the end of treatment.",[639,640,641,642],"Distalization","Class II Malocclusion","Aligner Therapy","Distalization by Miniscrews",[644,639,645,646,647],"Class II malocclusion","Orthodontics","Aligners","Miniscrew implants","2025-06-18",{"date":650,"type":44},"2025-06-27",{"date":652,"type":44},"2024-04-10",{"date":654,"type":22},"2028-04",{"name":50,"class":51},{"id":657,"slug":658,"hasResults":12,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":4,"eligibilityCriteria":662,"healthyVolunteers":162,"sex":255,"minAge":18,"maxAge":4,"enrollmentInfo":663,"targetDuration":665,"studyType":99,"phases":4,"briefSummary":666,"conditions":667,"keywords":674,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":683,"lastUpdatePostDateStruct":684,"startDateStruct":686,"completionDateStruct":688,"leadSponsor":690,"locationsCount":691},"100586658","association-of-assisted-reproductive-technologies-parameters-with-the-perinatal-outcome-100586658","NCT06918236","Association of Assisted Reproductive Technologies Parameters With the Perinatal Outcome","Association of Assisted Reproductive Technologies Parameters With the Perinatal Outcome in Singleton and Multiple Pregnancies: A Multicenter Prospective Cohort Study","Inclusion Criteria\n\n* Singleton or multiple pregnancies\n* Live fetus between 11 weeks plus 0 days and 13 weeks plus 6 days of gestation\n\nExclusion Criteria\n\n* Known genetic anomalies diagnosed before or after birth\n* Major fetal defects diagnosed before or after birth, such as acrania, holoprosencephaly, megacystis, exomphalos, congenital heart defects",{"count":664,"type":22},12084,"9 Months","The goal of this prospective cohort study is to examine how different parameters of assisted reproductive technologies (ART) are associated with the perinatal outcome in individuals with singleton or multiple gestations. The main questions it aims to answer are:\n\nAre ART pregnancies associated with a higher risk of:\n\n* Small for gestational age neonates?\n* Fetal growth restriction, either early- or late-onset?\n* Development of preeclampsia?\n* Stillbirth (intrauterine fetal death after 22 weeks not due to known anomalies)?\n* Are certain ART parameters-such as the type of fertilization (e.g., IVF vs. ICSI), embryo stage at transfer, use of fresh vs. frozen embryos, or ovarian stimulation protocols-more strongly associated with adverse outcomes?\n\nAre ART pregnancies associated with placental and umbilical cord abnormalities, including:\n\n* Placenta previa?\n* Vasa previa?\n* Single umbilical artery?\n* Velamentous or marginal cord insertion?\n\nResearchers will compare outcomes between pregnancies conceived through ART and those conceived spontaneously.\n\nParticipants will:\n\n* Be individuals aged 18 or older undergoing routine first-trimester ultrasound between 11 and 14 weeks of gestation\n* Provide detailed medical, obstetric, and ART-related information\n* Undergo routine prenatal assessments, including ultrasound evaluations of fetal growth, Doppler studies, and placental characteristics\n* Have perinatal outcomes such as gestational age at birth, mode of delivery, birthweight, and complications systematically recorded\n\nStatistical models will be used to adjust for confounding factors such as maternal age, BMI, parity, and smoking.\n\nThe aim is to better understand how ART and specific ART parameters may influence maternal and neonatal health and to improve counseling and clinical care for people using fertility treatments.",[668,669,670,671,672,673],"Fetal Growth Restriction (FGR)","Preeclampsia","Stillbirth","Placenta Previa","Vasa Previa","Small for Gestational Age (SGA)",[675,669,676,677,678,679,680,673,681,682],"fetal growth restriction","stillbirth","placenta previa","vasa previa","Assisted reproductive techniques","ART","IVF","ICSI","2025-04-05",{"date":685,"type":44},"2025-04-09",{"date":687,"type":44},"2024-10-01",{"date":689,"type":22},"2028-12",{"name":50,"class":51},6,{"id":693,"slug":694,"hasResults":12,"nctId":695,"briefTitle":696,"officialTitle":697,"acronym":4,"eligibilityCriteria":698,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":699,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":701,"conditions":702,"keywords":704,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":707,"lastUpdatePostDateStruct":708,"startDateStruct":710,"completionDateStruct":712,"leadSponsor":714,"locationsCount":86},"100586278","pteye-in-parathyroid-adenoma-100586278","NCT06913296","PTeye in Parathyroid Adenoma","Do PTeye Score Correlate With Biochemical Markers in Parathyroid Adenoma?","Inclusion Criteria:\n\n* Age \\>18 years old\n* primary hyperparathyroidism caused by adenoma\n* patient's informed consent acquired\n\nExclusion Criteria:\n\n* Secondary and tertiary hyperparathyroidism\n* Re-operation for adenoma\n* Previous neck surgery\n* Patient enrolled in another study that may affect the results of this study",{"count":700,"type":22},50,"Identifying the parathyroids is compulsory for success of parathyroidectomy for parathyroid adenoma. Near-infrared autofluorescence devices have been proposed as useful intraoperative tools for the identification of parathyroid glands. The aim of the present study is to evaluate the correlation of PTeye autofluorescence device with biochemical data of parathyroid adenoma patients.",[703],"Parathyroid Adenoma",[705,706],"parathyroid adenoma","near-infrared autofluorescence","2025-03-30",{"date":709,"type":44},"2025-04-06",{"date":711,"type":44},"2025-03-28",{"date":713,"type":22},"2025-05-30",{"name":50,"class":51},{"id":716,"slug":717,"hasResults":12,"nctId":718,"briefTitle":719,"officialTitle":720,"acronym":721,"eligibilityCriteria":722,"healthyVolunteers":162,"sex":17,"minAge":723,"maxAge":427,"enrollmentInfo":724,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":726,"conditions":727,"keywords":731,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":735,"lastUpdatePostDateStruct":736,"startDateStruct":738,"completionDateStruct":740,"leadSponsor":742,"locationsCount":86},"100572304","corneal-biomechanics-optical-properties-and-anterior-segment-structural-features-in-patients-with-pseudoexfoliation-100572304","NCT06731530","Corneal Biomechanics, Optical Properties and Anterior Segment Structural Features in Patients With Pseudoexfoliation","A Comparative Study of Anterior Segment Structural Features, Biomechanical Behaviour and Optical Properties of the Cornea in Patients With and Without Pseudoexfoliation Syndrome.","CorPEX","Inclusion Criteria:\n\n* age 60-80 years.\n* unilateral or bilateral pseudophakia (cataract surgery undergone at Papageorgiou General Hospital, Thessaloniki, Greece).\n* open anterior chamber angle (grade \\> 2, van Herick method).\n\nExclusion Criteria:\n\n* History of intraocular surgery other than uncomplicated cataract surgery (phakoemulsification).\n* Cataract surgery within the last 3 months.\n* History of ocular trauma.\n* Use of contact lenses.\n* Corneal pathology.\n* Use of anti-VEGF medications.\n* History of uveitis or active uveitis.\n* Hypertension (IOP \\> 21 mmHg) or glaucoma.\n* Myopia or hyperopia greater than 3 diopters.\n* Astigmatism greater than 1.5 diopters.\n* Posterior capsular opacification grade 2, 3, or 4 based on the EPCO grading scale.\n* Tear break-up time \\\u003C10 sec","60 Years",{"count":725,"type":22},86,"The purpose of this study is to assess the effect of pseudoexfoliation syndrome on corneal biomechanics, optical clarity of the cornea, and anterior segment structural features.",[728,729,730],"Pseudoexfoliation Syndrome","Biomechanical Parameters","Corneal Densitometry",[732,733,734],"pseudoexfoliation syndrome","biomechanical parameters","corneal transparency","2024-12-24",{"date":737,"type":44},"2024-12-27",{"date":739,"type":44},"2024-12-13",{"date":741,"type":22},"2025-05",{"name":50,"class":51},""]